NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis $0.95 -0.08 (-7.77%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.98 +0.03 (+3.16%) As of 03/28/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clearside Biomedical Stock (NASDAQ:CLSD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Clearside Biomedical alerts:Sign Up Key Stats Today's Range$0.95▼$1.0350-Day Range$0.79▼$1.1352-Week Range$0.77▼$1.65Volume289,511 shsAverage Volume355,754 shsMarket Capitalization$72.05 millionP/E RatioN/ADividend YieldN/APrice Target$5.25Consensus RatingBuy Company OverviewClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Read More… Remove Ads Clearside Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreCLSD MarketRank™: Clearside Biomedical scored higher than 47% of companies evaluated by MarketBeat, and ranked 622nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has only been the subject of 3 research reports in the past 90 days.Read more about Clearside Biomedical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Clearside Biomedical's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.07% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently decreased by 4.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.07% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently decreased by 4.14%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.39 News SentimentClearside Biomedical has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Clearside Biomedical this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.20% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions.Read more about Clearside Biomedical's insider trading history. Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Stock News HeadlinesClearside Biomedical, Inc.: Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 29 at 12:47 AM | finanznachrichten.deStifel Nicolaus Sticks to Its Buy Rating for Clearside Biomedical (CLSD)March 29 at 12:47 AM | markets.businessinsider.comYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.March 29, 2025 | American Alternative (Ad)Clearside Biomedical price target lowered to $4 from $6 at NeedhamMarch 28 at 7:46 PM | markets.businessinsider.comClearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call TranscriptMarch 27 at 9:00 PM | seekingalpha.comClearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27 at 4:14 PM | globenewswire.comExploring Clearside Biomedical's Earnings ExpectationsMarch 27 at 1:56 AM | benzinga.comClearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMarch 24, 2025 | globenewswire.comSee More Headlines CLSD Stock Analysis - Frequently Asked Questions How have CLSD shares performed this year? Clearside Biomedical's stock was trading at $0.95 at the start of the year. Since then, CLSD shares have increased by 0.0% and is now trading at $0.95. View the best growth stocks for 2025 here. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings data on Thursday, March, 27th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The business had revenue of $0.31 million for the quarter, compared to analysts' expectations of $0.27 million. When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Top institutional investors of Clearside Biomedical include Geode Capital Management LLC (1.01%), Renaissance Technologies LLC (0.95%), First Manhattan CO. LLC. (0.53%) and Northern Trust Corp (0.22%). Insiders that own company stock include Bradford T Whitmore, George M Lasezkay, Charles A Deignan, Thomas Ciulla, Ngai Hang Victor Chong and Benjamin R Yerxa. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ). Company Calendar Last Earnings3/27/2025Today3/28/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLSD CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+452.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,490,000.00 Net Margins-413.83% Pretax Margin-413.83% Return on EquityN/A Return on Assets-92.90% Debt Debt-to-Equity RatioN/A Current Ratio4.49 Quick Ratio4.49 Sales & Book Value Annual Sales$7.70 million Price / Sales9.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-3.80Miscellaneous Outstanding Shares75,844,000Free Float68,866,000Market Cap$72.05 million OptionableOptionable Beta2.10 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CLSD) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.